Skip to main navigation Skip to search Skip to main content

The Progression of Bone Mineral Density Abnormalities after Chemotherapy for Childhood Acute Lymphoblastic Leukemia

  • Nicholas A. Vitanza
  • , Laura E. Hogan
  • , Guangxiang Zhang
  • , Robert I. Parker

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Although reduced bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL) is well documented, the degree of demineralization and relation to age are not well described. This is a retrospective chart analysis of 58 patients consecutively treated for ALL without relapse, cranial irradiation, or transplantation. Bone mineral densities were measured by dual-energy x-ray absorptiometry and patients were divided by sex and age (≤5, 6 to 10, and >10 y) at diagnosis. Serial scans for 6 years after therapy were analyzed as Z-scores. Over 6 years after therapy, 93.1% of patients exhibited a decreased Z-score in at least 1 anatomic site. The difference in Z-score among the age cohorts was significant at both the lumbar spine and femoral neck. Patients older than 10 years at diagnosis had the lowest Z-scores: -2.78 and -2.87 for boys and -2.39 and -2.91 for girls at the lumbar spine and femoral neck, respectively. Children after ALL therapy exhibit a significant bone mineral deficit shortly after completion of therapy that persists for at least 6 years. The degree of bone demineralization can be followed up by a dual-energy x-ray absorptiometry scan and is most severe in patients older than 10 years at the initiation of therapy.

Original languageEnglish
Pages (from-to)356-361
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume37
Issue number5
DOIs
StatePublished - Jul 11 2015

Keywords

  • bone
  • childhood ALL
  • demineralization
  • late effects
  • leukemia
  • osteoporosis

Fingerprint

Dive into the research topics of 'The Progression of Bone Mineral Density Abnormalities after Chemotherapy for Childhood Acute Lymphoblastic Leukemia'. Together they form a unique fingerprint.

Cite this